Press Releases
Study shows that in HER2 positive early breast cancer 6 months treatment with Herceptin is as good as 12 months for preventing cancer return
A new study co-led by the University of Warwick Clinical Trials Unit has shown that shortening the duration of a therapy for breast cancer patients does not increase the risk of their cancer returning.
Novel anti-cancer drug delivery system being presented in Parliament by Warwick student
Sean Ellacott, 25, a third year PhD student at the University of Warwick, , is attending Parliament to present his chemistry research about the interaction of self-assembling nanotubes with biological models, which are currently being considered for the delivery of anticancer drugs, to a range of politicians and a panel of expert judges, as part of STEM for BRITAIN on Wednesday 13 March.
Simply shining light on dinosaur metal compound kills cancer cells
A new compound based on Iridium, a rare metal which landed in the Gulf of Mexico 66 M years ago, hooked onto albumin, a protein in blood, can attack the nucleus of cancerous cells when switched on by light, University of Warwick researchers have found.
Standard chemotherapy treatment for HPV-positive throat cancer remains the most effective, study finds
A new study funded by Cancer Research UK and sponsored by the University of Warwick has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.
Warwick awarded £2.3 million to help develop cutting-edge technologies for cancer diagnosis and personalised treatment
Greg Clark, UK Secretary of State for Business, Energy and Industrial Strategy (BEIS), will confirm today (Tuesday 6 November) that UK Research and Innovation will invest £10 million in the PathLAKE project as part of the Industrial Strategy Challenge Fund. The University of Warwick has been awarded £2.3 million of the funding which will be used to create innovative solutions in digital pathology and Artificial Intelligence (AI) to speed up the time in which cancer is diagnosed and treated.
Six months of Herceptin could be as effective as 12 months for some women with HER2 positive breast cancer
Study that finds women with HER2 positive early-stage breast cancer taking Herceptin for six months could be as effective as 12 months in preventing relapse and death, and can reduce side effects, finds new research.